Bibliography
- ROSEN R, ALTWEIN J, BOYLE P etal.: Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol. (2003) 44(6):637-649.
- BERRY SJ, COFFEY DS, WALSH PC, EWING LL: The development of benign prostatic hyperplasia with age. J. Urol. (1984) 132:474-479.
- MCKINLAY JB: The worldwide prevalence and epidemiology of erectile dysfunction. Int. J. Impot. Res. (2000) 12(Suppl.4):S6-S11.
- PEARLMAN CK, KOBASHI LI: Frequency of intercourse in men. J. Urol. (1972) 107:298-301.
- BRAUN M, WASSMER G, KLOTZ T etal.: Epidemiology of erectile dysfunction: results of the Cologne Male Survey. Int. J. Impot. Res. (2000) 12:305-311.
- GIRMAN CJ, JACOBSEN SJ, RHODEST etal.: Association of health-related quality of life and benign prostatic enlargement. Eur. Urol. (1999) 35:277-284.
- YASSIN A, SAAD F, HOESL CE etal.: -Adrenoreceptors are a common denominator in the pathophysilogy of erectile function and BPH/LUTS implications for clinical practice. Andrologia (2006) 38:1-12.
- KHAN MA, THOMPSON CS, DASHWOOD MR etal.: Endothelin-1 and nitric oxide in the pathogenesis of urinary tract disorders secondary to bladder outlet obstruction. Curr. Vasc. Pharmacol. (2003) 1(1):27-31.
- ANDERSSON KE, CHAPPLE CR, HOFNER K: Future drugs for the treatment of benign prostatic hyperplasia. World J. Urol. (2002) 19(6):436-442.
- GRADINI R, REALACCI M, GINEPRI A etal.: Nitric oxide synthases in normal and benign hyperplastic human prostate: immunohistochemistry and molecular biology. J. Pathol. (1999) 189(2):224-229.
- CHITALEY K, WINGARD C, WEBB RC etal.: Antagonism of rho-kinase stimulates rat penile erection via a nitric oxide-independent pathway. Nat. Med. (2001) 7:119-122.
- BING W, CHANG S, HYPOLITE JA etal.: Obstruction-induced changes in urinary bladder smooth muscle contractility: a role for Rho kinase. Am. J. Physiol. Renal Physiol. (2003) 285:F990-F997.
- CHANG S, HYPOLITE JA, ZDERIC A etal.: Increased corpus cavernosum smooth muscle tone associated with partial bladder outlet obstruction is mediated via Rho-kinase. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2005) 289:R1124-R1130.
- DEEDWANIA PC: Mechanisms of endothelial dysfunction in the metabolic syndrome. Curr. Diabetes Rep. (2003) 3:289-292.
- SCHIFF JD, MULHALL JP: The link between LUTS and ED: clinical and basic science evidence. J. Androl. (2004) 25(4):470-478.
- CALVERT RC, KHAN MA, THOMPSON CS etal.: Alterations in nitric oxide signaling provides insight into the pathophysiology of erectile dysfunction associated with benign prostatic hyperplasia. Paper presented at: The American Urological Association Annual Meeting. Anaheim, CA, USA (2001).
- UCKERT S, KUTHE A, JONAS U etal.: Characterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate. J. Urol. (2001) 166:2484-2490.
- BURNETT AL: Nitric oxide control of lower genitourinary tract functions: a review. Urology (1995) 45(6):1071-1083.
- TAKEDA M, TANG R, SHAPIRO E etal.: Effects of nitric oxide on human and canine prostates. Urology (1995) 45(3):440-446.
- MOON A: Influence of nitric oxide signalling pathways on pre-contracted human detrusor smooth muscle invitro. BJU Int. (2002) 89(9):942-949.
- MCCONNELL JD, ROEHRBORN CG, BAUTISTA AM etal.; for the MTOPS research group: The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N. Engl. J. Med. (2003) 349(25):2387-2398.
- HOPPS CV, MULHALL JP: Assessment of the impact of sildenafil citrate on lower urinary tract symptoms (LUTS) in men with erectile dysfunction (ED). J. Sex. Med. (2006) (In Press).
- KAPLAN SA, REIS RB, KOHN IJ etal.: Combination therapy using oral -blockers and intracavernosal injection in men with erectile dysfunction. Urology (1998) 52(5):739-743.
- KAPLAN SA, GONZALEZ RR, OGISTEJ etal.: Combination of an -blocker, alfuzosin SR, and a PDE-5 inhibitor, sildenafil citrate, is superior to monotherapy in treating lower urinary tract symptoms (LUTS) and sexual dysfunction. J. Urol. (2006) 175(4):528.
- ROEHRBORN C, MCVARY K, KAMINETSKY J etal.: The efficacy and safety of tadalafil administered once a day for lower urinary tract symptoms (LUTS) in men with benign prostatic hyperplasia (BPH). J. Urol. (2006) 175(4):527.
- ANGULO J, GADAU M, FERNANDEZA etal.: IC-351 enhances nitric oxide-mediated relaxation of human arterial and trabecular penile smooth muscle. Diabetologia (2001) 44(Suppl.1):A295.
- CURRAN MP, KEATING GM: Tadalafil. Drugs (2003) 63(20):2203-2212.
- MEULEMAN EJH: Review of tadalafil in the treatment of erectile dysfunction. Expert Opin. Pharmacother. (2003) 4(11):2049-2056.
- PATTERSON B, BEDDING A, JEWELLH etal.: Dose-normalised pharmacokinetics of tadalafil administered as a single dose to healthy volunteers. Eur. Urol. (2002) 41(Suppl. 1):152.
- PORST H: IC-351 (tadalafil, Cialis): update on clinical experience. Int. J. Impot. Res. (2002) 14(Suppl. 1):S57-S64.
- PATTERSON B, BEDDING A, JEWELLH etal.: The effect of intrinsic and extrinsic factors on the pharmacokinetic properties of tadalafil (IC-351). Presented at: The European Society for Sexual and Impotence Research. Rome, Italy (2001).
- HUTTER AM, KLONER RA, WATKINSversus etal.: Poster, presented at: The 17th Annual Scientific Meeting of the American Society of Hypertension (ASH). New York, NY, USA (2002).
- KLONER RA: Pharmacology and drug interaction effects of phosphodiesterase 5 inhibitors: focus on -blocker interactions. Am. J. Cardiol. (2005) 96(12B):42M-46M.
- KLONER RA, JACKSON G, EMMICKJT etal.: Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 -blockers, doxazosin and tamsulosin in healthy normotensive men. J. Urol. (2004) 172(5 Pt 1):1935-1940.
- HELLSTROM W, OVERSTREET JW, YUA etal.: Tadalafil has no effect on spermatogenesis or reproductive hormones. J. Urol. (2003) 169(Suppl. 4):245.
- HAYREH SS: Erectile dysfunction drugs and non-arteritic anterior ischemic optic neuropathy: is there a cause and effect relationship? J. Neuroophthalmol. (2005) 25(4):295-298.